EZH2, the catalytic subunit of PRC2, catalyzes histone H3 lysine 27 (H3K27) trimethylation
to induce the agglutination of chromosomes and in turn represses the transcription of the …

Prostate cancer is the most frequent nonskin cancer and second most common cause of
cancer-related deaths in man. Prostate cancer is a clinically heterogeneous disease with …

Background Hormonal therapy targeting the androgen receptor inhibits prostate cancer
(PCa), but the tumor eventually recurs as castration-resistant prostate cancer (CRPC) …

Exosomal microRNAs (miRNAs) have been implicated in the development and progression
of a variety of tumors; however, whether they contribute to medulloblastoma (MB) …

Abstract Analysis of DNA methylation is a valuable tool to understand disease progression
and is increasingly being used to create diagnostic and prognostic clinical biomarkers …

Hepatocellular carcinoma (HCC) is a widespread, common type of cancer in Asian
countries, and the need for biomarker-matched molecularly targeted therapy for HCC has …

Background: Topoisomerase IIA (TOP2A) gene encodes DNA topoisomerase enzyme and
has been reported that TOP2A is broadly expressed in many types of cancers. Our study …

The gut microbiota modulates response to hormonal treatments in prostate cancer (PCa)
patients, but whether it influences PCa progression remains unknown. Here, we show a …

Recent research has shown that TOP2A plays an important role in the tumorigenesis of
many malignancies, such as breast cancer, ovarian cancer, and prostate cancer. However …

Background The link between prostate cancer (PCa) development and aberrant expression
of genes located on the Y chromosome remains unclear. Objective To identify Y …